Form D · Biotechnology
Pierogi Therapeutics, Inc
Pittsburgh, PA · CIK 0002139858
Offering snapshot reported Jun 17, 2026 · SEC filing
- Reported sold
- $50K Offering amount: $4M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 9, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 17, 2026 | Initial | $50,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-587688
Source: Form D, filed Jun 17, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Filipp Gusev | Director, Executive |
| Samuel Benjamin Koby | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5533 Beacon St
Pittsburgh, PA, 15217
Pittsburgh, PA, 15217